The Oncosearch | Oncotarget

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms Research Paper

Katerina Zakka, Rebecca Nagy, Leylah Drusbosky, Mehmet Akce, Christina Wu, Olatunji B. Alese, Bassel F. El-Rayes, Pashtoon Murtaza Kasi, Kabir Mody, Jason Starr, Walid L. Shaib

Published Apr 26, 2020 · Vol. 11, No. 19 · pp. 1749-1757

Keywords: neuroendocrine neoplasm, neuroendocrine tumor, neuroendocrine carcinoma, next-generation sequencing, circulating tumor DNA

Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study Research Paper

Beatrice Aramini, Federico Banchelli, Stefania Bettelli, Samantha Manfredini, Roberto D’Amico, Valentina Masciale, Massimo Pinelli, Margherita Moretti, Alessandro Stefani, Federica Bertolini, Massimo Dominici, Uliano Morandi, Antonino Maiorana

Published Feb 4, 2020 · Vol. 11, No. 5 · pp. 550-559

Keywords: somatic mutations, non-small cell lung cancer (NSCLC), lung cancer treatment, overall survival, target therapy

Correction: Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQ^Q209P-driven uveal melanomas in zebrafish Correction

Mai Abdel Mouti, Christopher Dee, Sarah E. Coupland, Adam F.L. Hurlstone

Published Jan 26, 2020

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Hengyu Lu, Chen Liu, Hung Huynh, Thi Bich Uyen Le, Matthew J. LaMarche, Morvarid Mohseni, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Huai-Xiang Hao

Published Jan 21, 2020 · Vol. 11, No. 3 · pp. 265-281

Keywords: SHP2, FGFR, resistance, feedback activation

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Hengyu Lu, Chen Liu, Hung Huynh, Thi Bich Uyen Le, Matthew LaMarche, Morvarid Mohseni, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Huai-Xiang Hao

Published Jan 6, 2020

Keywords: SHP2, FGFR, resistance, feedback activation

BRAF^V600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma Research Paper

M. Herman Chui, Susanne K. Kjaer, Kirsten Frederiksen, Charlotte G. Hannibal, Tian-Li Wang, Russell Vang, Ie-Ming Shih

Published Dec 3, 2019 · Vol. 10, No. 64 · pp. 6870-6878

Keywords: ovarian serous borderline tumor, mutation, genotyping, risk prediction, serous carcinoma

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Rowland H. Han, Gavin P. Dunn, Milan G. Chheda, Albert H. Kim

Published Nov 19, 2019 · Vol. 10, No. 62 · pp. 6739-6753

Keywords: brain metastases, targeted therapy, precision medicine, immunotherapy, systemic therapy

The multifaceted anti-cancer effects of BRAF-inhibitors Review

Laura Croce, Francesca Coperchini, Flavia Magri, Luca Chiovato, Mario Rotondi

Published Nov 12, 2019 · Vol. 10, No. 61 · pp. 6623-6640

Keywords: BRAF, BRAF-inhibitors, tumor microenvironment, chemokines, CXCL8

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes Research Paper

Francesca Coperchini, Laura Croce, Marco Denegri, Oriana Awwad, Samuel Tata Ngnitejeu, Flavia Magri, Luca Chiovato, Mario Rotondi

Published Nov 5, 2019 · Vol. 10, No. 60 · pp. 6432-6443

Keywords: phenformin, tumor-microenvironment, thyroid cancer, CXCL8

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo Research Paper

Sean M. Flynn, Jacqueline Lesperance, Andrew Macias, Nikki Phanhthilath, Megan Rose Paul, Jong Wook Kim, Pablo Tamayo, Peter E. Zage

Published Oct 29, 2019 · Vol. 10, No. 59 · pp. 6323-6333

Keywords: neuroblastoma, RXDX-105, CEP-32496, RET, BRAF

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report Case Report

Mayank Rao, Meenakshi Bhattacharjee, Scott Shepard, Sigmund Hsu

Published Oct 15, 2019 · Vol. 10, No. 57 · pp. 6038-6042

Keywords: papillary, craniopharyngioma, BRAF V600E, dabrafenib, neuro-oncology

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center Research Paper

Noura J. Choudhury, Mansooreh Eghtesad, Sabah Kadri, John Cursio, Lauren Ritterhouse, Jeremy Segal, Aliya Husain, Jyoti D. Patel

Published Oct 8, 2019 · Vol. 10, No. 56 · pp. 5817-5823

Keywords: non-small cell lung cancer, healthcare disparities, targeted therapies, immunotherapies, biomarkers

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo Research Paper

Elgilda Musi, Gary K. Schwartz, Jae Hyuk Yoo, Shannon J. Odelberg, Dean Y. Li, Michael Y. Bonner, Ponniah Selvakumar, Shikha Rao, Linda C. Gilbert, Justin Elsey, Jack L. Arbiser

Published Jul 9, 2019 · Vol. 10, No. 43 · pp. 4424-4436

Keywords: melanoma, chemotherapy

Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool Research Paper

Ali Sakhdari, Parnian Ahmadi Moghaddam, Chi Young Ok, Otto Walter, Keith Tomaszewicz, Mandi-Lee Caporelli, Xiuling Meng, Jennifer LaFemina, Giles Whalen, Edward Belkin, Jaroslav Zivny, Wahid Wassef, Bruce A. Woda, Lloyd M. Hutchinson, Ediz F. Cosar

Published Jun 18, 2019 · Vol. 10, No. 40 · pp. 4026-4037

Keywords: pancreatic cyst classification, non-diagnostic cytology, molecular next generation sequencing

Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology–morphological and therapeutic implications Research Paper

Maria-Magdalena Georgescu, Yan Li, Mohammad Zahidul Islam, Christina Notarianni, Hai Sun, Adriana Olar, Gregory N. Fuller

Published Jun 18, 2019 · Vol. 10, No. 40 · pp. 4038-4052

Keywords: epithelioid glioblastoma, SEGA-like, mTOR, MAPK, 4E-BP1

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor Research Paper

Tomasz Kolenda, Piotr Rutkowski, Michał Michalak, Katarzyna Kozak, Kacper Guglas, Marcel Ryś, Łukasz Galus, Sebastian Woźniak, Iwona Ługowska, Aleksandra Gos, Anna Teresiak, Andrzej Mackiewicz, Katarzyna Lamperska, Jacek Mackiewicz

Published Jun 11, 2019 · Vol. 10, No. 39 · pp. 3879-3893

Keywords: melanoma, BRAF mutation, BRAF inhibitor, lncRNA, liquid biopsy

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study Research Paper

Stefano Guadagni, Giammaria Fiorentini, Andrea Mambrini, Francesco Masedu, Marco Valenti, Andrew Reay Mackay, Donatella Sarti, Enrico Ricevuto, Marco Clementi, Marco Catarci, Gianni Lazzarin, Gemma Bruera

Published Jun 11, 2019 · Vol. 10, No. 39 · pp. 3840-3851

Keywords: hypoxic pelvic perfusion with mitomycin C and oxaliplatin, unresectable recurrent rectal cancer, retrospective cohort study

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Peter Y.M. Woo, Tai-Chung Lam, Jenny K.S. Pu, Lai-Fung Li, Roland C.Y. Leung, Jason M.K. Ho, James T.F. Zhung, Belinda Wong, Timonthy S.K. Chan, Herbert H.F. Loong, Ho-Keung Ng

Published Jun 4, 2019 · Vol. 10, No. 38 · pp. 3818-3826

Keywords: glioblastoma, BRAF^V600E mutation, targeted therapies, BRAF-MEK inhibitors

Dissecting the role of RNA modification regulatory proteins in melanoma Research Paper

Parmanand Malvi, Biao Wang, Shreni Shah, Romi Gupta

Published Jun 4, 2019 · Vol. 10, No. 38 · pp. 3745-3759

Keywords: RNA modifications, epitranscriptome, melanoma, MAPK, BRAF mutant melanoma

Melanoma patients with additional primary cancers: a single-center retrospective analysis Research Paper

Florentia Dimitriou, Joanna Mangana, Alessandra Curioni-Fontecedro, Markus Rechsteiner, Patrick Turko, Ralph P. Braun, Reinhard Dummer, Phil F. Cheng

Published May 21, 2019 · Vol. 10, No. 36 · pp. 3373-3384

Keywords: melanoma, additional primary tumors, multiple primary tumors, BRAF V600E mutation, papillary thyroid cancer

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms Research Paper

Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study Research Paper

Correction: Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQ^Q209P-driven uveal melanomas in zebrafish Correction

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

BRAF^V600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma Research Paper

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

The multifaceted anti-cancer effects of BRAF-inhibitors Review

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes Research Paper

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo Research Paper

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report Case Report

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center Research Paper

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo Research Paper

Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool Research Paper

Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology–morphological and therapeutic implications Research Paper

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor Research Paper

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study Research Paper

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Dissecting the role of RNA modification regulatory proteins in melanoma Research Paper

Melanoma patients with additional primary cancers: a single-center retrospective analysis Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms Research Paper

Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study Research Paper

Correction: Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish Correction

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma Research Paper

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

The multifaceted anti-cancer effects of BRAF-inhibitors Review

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes Research Paper

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo Research Paper

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report Case Report

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center Research Paper

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo Research Paper

Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool Research Paper

Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology–morphological and therapeutic implications Research Paper

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor Research Paper

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study Research Paper

Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Dissecting the role of RNA modification regulatory proteins in melanoma Research Paper

Melanoma patients with additional primary cancers: a single-center retrospective analysis Research Paper

Correction: Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQ^Q209P-driven uveal melanomas in zebrafish Correction

BRAF^V600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma Research Paper

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report